96 related articles for article (PubMed ID: 19845766)
21. Effects of sphingosylphosphorylcholine against cholestatic oxidative stress and liver damage in the common bile duct ligated rats.
Aksu B; Umit H; Kanter M; Guzel A; Inan M; Civelek S; Aktas C; Uzun H
J Pediatr Surg; 2009 Apr; 44(4):702-10. PubMed ID: 19361629
[TBL] [Abstract][Full Text] [Related]
22. The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants.
Heresi GP; Gerstmann DR; Reed MD; van den Anker JN; Blumer JL; Kovanda L; Keirns JJ; Buell DN; Kearns GL
Pediatr Infect Dis J; 2006 Dec; 25(12):1110-5. PubMed ID: 17133155
[TBL] [Abstract][Full Text] [Related]
23. Assessment of micafungin regimens by pharmacokinetic-pharmacodynamic analysis: a dosing strategy for Aspergillus infections.
Ikawa K; Nomura K; Morikawa N; Ikeda K; Taniwaki M
J Antimicrob Chemother; 2009 Oct; 64(4):840-4. PubMed ID: 19700475
[TBL] [Abstract][Full Text] [Related]
24. Altered Micafungin Pharmacokinetics in Intensive Care Unit Patients.
Lempers VJ; Schouten JA; Hunfeld NG; Colbers A; van Leeuwen HJ; Burger DM; Verweij PE; Pickkers P; Brüggemann RJ
Antimicrob Agents Chemother; 2015 Aug; 59(8):4403-9. PubMed ID: 25963988
[TBL] [Abstract][Full Text] [Related]
25. Micafungin.
Bell SG
Neonatal Netw; 2011; 30(5):329-33. PubMed ID: 21846628
[No Abstract] [Full Text] [Related]
26. Long-term diabetes alters the hepatobiliary clearance of acetaminophen, bilirubin and digoxin.
Watkins JB; Sherman SE
J Pharmacol Exp Ther; 1992 Mar; 260(3):1337-43. PubMed ID: 1545396
[TBL] [Abstract][Full Text] [Related]
27. Mechanism of the tissue distribution and biliary excretion of the cyclic peptide octreotide.
Yamada T; Niinuma K; Lemaire M; Terasaki T; Sugiyama Y
J Pharmacol Exp Ther; 1996 Dec; 279(3):1357-64. PubMed ID: 8968360
[TBL] [Abstract][Full Text] [Related]
28. Biliary drainage attenuates postischemic reperfusion injury in the cholestatic rat liver.
Kloek JJ; Marsman HA; van Vliet AK; Gouma DJ; van Gulik TM
Surgery; 2008 Jul; 144(1):22-31. PubMed ID: 18571581
[TBL] [Abstract][Full Text] [Related]
29. Impaired response to alloantigens in murine biliary obstruction.
Nie CH; Grogan JB; Crick MP; Scott-Conner CE
J Surg Res; 1993 Feb; 54(2):145-9. PubMed ID: 8479173
[TBL] [Abstract][Full Text] [Related]
30. Increased melibiose/rhamnose ratio in bile of rats with acute cholestasis.
Tomsik P; Sispera L; Rezacova M; Niang M; Stoklasova A; Cerman J; Knizek J; Brcakova E; Cermanova J; Micuda S
J Gastroenterol Hepatol; 2008 Dec; 23(12):1934-40. PubMed ID: 18717760
[TBL] [Abstract][Full Text] [Related]
31. Disposition of amphotericin B in the isolated perfused rat liver.
Hong Y; Ramzan I; McLachlan AJ
J Pharm Pharmacol; 2004 Jan; 56(1):35-41. PubMed ID: 14979999
[TBL] [Abstract][Full Text] [Related]
32. Biliary excretion of pravastatin in rats: contribution of the excretion pathway mediated by canalicular multispecific organic anion transporter.
Yamazaki M; Akiyama S; Ni'inuma K; Nishigaki R; Sugiyama Y
Drug Metab Dispos; 1997 Oct; 25(10):1123-9. PubMed ID: 9321514
[TBL] [Abstract][Full Text] [Related]
33. Dehydroepiandrosterone sulphate improves cholestasis-associated fatigue in bile duct ligated rats.
Butterworth RF; Lalonde R; Power C; Baker GB; Gamrani H; Ahboucha S
Neurogastroenterol Motil; 2009 Dec; 21(12):1319-25. PubMed ID: 19594690
[TBL] [Abstract][Full Text] [Related]
34. Experimental cholestatic liver disease through bile-duct ligation in rats results in skeletal fragility and impaired osteoblastogenesis.
Weinreb M; Pollak RD; Ackerman Z
J Hepatol; 2004 Mar; 40(3):385-90. PubMed ID: 15123350
[TBL] [Abstract][Full Text] [Related]
35. Disposition and metabolism of the new hypocholesterolemic compound S-8921 in rats and dogs.
Yamaguchi T; Nakajima Y; Mizobuchi M; Inazawa K; Kanazu T; Kadono K; Ohkawa T; Iwatani K
Arzneimittelforschung; 1998 Oct; 48(10):995-1006. PubMed ID: 9825117
[TBL] [Abstract][Full Text] [Related]
36. Progressive decrease in tissue glycogen content in rats with long-term cholestasis.
Krahenbuhl L; Talos C; Reichen J; Krähenbuhl S
Hepatology; 1996 Oct; 24(4):902-7. PubMed ID: 8855195
[TBL] [Abstract][Full Text] [Related]
37. Impaired biliary excretion and whole body elimination of methylmercury in rats with congenital defect in biliary glutathione excretion.
Ballatori N; Gatmaitan Z; Truong AT
Hepatology; 1995 Nov; 22(5):1469-73. PubMed ID: 7590665
[TBL] [Abstract][Full Text] [Related]
38. Penetration of micafungin into the burn eschar in patients with severe burns.
Sasaki J; Yamanouchi S; Sato Y; Abe S; Shinozawa Y; Kishino S; Aikawa N; Hori S
Eur J Drug Metab Pharmacokinet; 2014 Jun; 39(2):93-7. PubMed ID: 23771854
[TBL] [Abstract][Full Text] [Related]
39. Maintenance of therapeutic concentrations of micafungin administered 5 days/week in a leukemic adolescent with invasive candidiasis.
Castagnola E; Cangemi G; Barco S; Bandettini R; Dallorso S; Virga F; Dufour C
Clin Microbiol Infect; 2014 Nov; 20(11):O975-6. PubMed ID: 24621154
[No Abstract] [Full Text] [Related]
40. Proliferation and phenotypic modulation of portal fibroblasts in the early stages of cholestatic fibrosis in the rat.
Tuchweber B; Desmoulière A; Bochaton-Piallat ML; Rubbia-Brandt L; Gabbiani G
Lab Invest; 1996 Jan; 74(1):265-78. PubMed ID: 8569191
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
